An Alzheimer's disease-specific β-amyloid fragment signature in cerebrospinal fluid
暂无分享,去创建一个
Anders Wallin | Henrik Zetterberg | Kaj Blennow | Ulf Andreasson | Ann Westman-Brinkmalm | Gunnar Brinkmalm | K. Blennow | H. Zetterberg | A. Wallin | N. Andreasen | U. Andréasson | E. Portelius | A. Westman-Brinkmalm | G. Brinkmalm | Niels Andreasen | Erik Portelius | U. Andreasson | A. Westman‐Brinkmalm
[1] Lennart Eriksson,et al. Model validation by permutation tests: Applications to variable selection , 1996 .
[2] Gerrit Schüürmann,et al. Quantitative structure-activity relationships in environmental sciences, VII , 1997 .
[3] D. Selkoe. Alzheimer's disease: genes, proteins, and therapy. , 2001, Physiological reviews.
[4] D. Selkoe,et al. Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids , 1992, Nature.
[5] K. Blennow,et al. Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. , 1999, Archives of neurology.
[6] Alistair Burns,et al. Observations on the brains of demented old people. B.E. Tomlinson, G. Blessed and M. Roth, Journal of the Neurological Sciences (1970) 11, 205–242; (1968) 7, 331–356 , 1997 .
[7] M. Folstein,et al. Clinical diagnosis of Alzheimer's disease , 1984, Neurology.
[8] L. Forno,et al. P3 beta-amyloid peptide has a unique and potentially pathogenic immunohistochemical profile in Alzheimer's disease brain. , 1996, The American journal of pathology.
[9] S. Sisodia. Beta-amyloid precursor protein cleavage by a membrane-bound protease. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[10] R. Nitsch,et al. Cerebrospinal Fluid Profile of Amyloid β Peptides in Patients with Alzheimer’s Disease Determined by Protein Biochip Technology , 2004, Neurodegenerative Diseases.
[11] D. Beher,et al. Generation of C‐terminally truncated amyloid‐β peptides is dependent on γ‐secretase activity , 2002 .
[12] Henrik Zetterberg,et al. Determination of β-Amyloid Peptide Signatures in Cerebrospinal Fluid Using Immunoprecipitation-Mass Spectrometry , 2006 .
[13] M. Ball,et al. Chemical characterization of A beta 17-42 peptide, a component of diffuse amyloid deposits of Alzheimer disease. , 1994, The Journal of biological chemistry.
[14] C. Vigo‐Pelfrey,et al. Rapid Communication: Characterization of β‐Amyloid Peptide from Human Cerebrospinal Fluid , 1993 .
[15] J. Kornhuber,et al. Highly conserved and disease‐specific patterns of carboxyterminally truncated Aβ peptides 1–37/38/39 in addition to 1–40/42 in Alzheimer's disease and in patients with chronic neuroinflammation , 2002, Journal of neurochemistry.
[16] S. Sahasrabudhe,et al. Release of amino-terminal fragments from amyloid precursor protein reporter and mutated derivatives in cultured cells. , 1992, The Journal of biological chemistry.
[17] D. Selkoe,et al. Kinetics of Amyloid β-Protein Degradation Determined by Novel Fluorescence- and Fluorescence Polarization-based Assays* , 2003, Journal of Biological Chemistry.
[18] C. Eckman,et al. Aβ-degrading enzymes: modulators of Alzheimer's disease pathogenesis and targets for therapeutic intervention , 2005 .
[19] N. Hooper,et al. ADAMs family members as amyloid precursor protein α‐secretases , 2003 .
[20] Erik Johansson,et al. QSAR Model Validation , 2000 .
[21] C. Eckman,et al. Degradation of the Alzheimer's Amyloid β Peptide by Endothelin-converting Enzyme* , 2001, The Journal of Biological Chemistry.
[22] D. Selkoe,et al. Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. , 2003, Annual review of pharmacology and toxicology.
[23] K. Blennow,et al. CSF markers for incipient Alzheimer's disease , 2003, The Lancet Neurology.
[24] H. Wiśniewski,et al. The “Nonamyloidogenic” p3 Fragment (Amyloid β17-42) Is a Major Constituent of Down's Syndrome Cerebellar Preamyloid* , 1996, The Journal of Biological Chemistry.